Portage Biotech Inc. (PRTG)
NASDAQ: PRTG · Real-Time Price · USD
5.42
0.00 (0.00%)
Aug 4, 2025, 11:51 AM - Market open
Accolade Employees
Portage Biotech had 7 employees as of March 31, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$966,714
Market Cap
12.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 7 | 0 | - |
| Mar 31, 2023 | 7 | 1 | 16.67% |
| Mar 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRTG News
- 9 days ago - Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 - GlobeNewsWire
- 5 weeks ago - Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire
- 2 months ago - Portage Biotech and Compedica Stock-for-Stock Exchange - GlobeNewsWire
- 3 months ago - Portage Biotech Stock Surges As It Prepares For Human Trial - Benzinga
- 3 months ago - Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - GlobeNewsWire
- 4 months ago - Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga
- 4 months ago - Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial - Market Watch
- 5 months ago - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - GlobeNewsWire